QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Monoclonal Antibodies—Classification by Mechanism of Action and Pharmacovigilance

Test your understanding of the concepts covered by Monoclonal Antibodies: Classification by Mechanism of Action and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes Fc-mediated effector function in the mechanistic framework?

It is always the primary mechanism of every IgG antibody It is a cross-cutting supporting determinant that may contribute to cell depletion or other effects It replaces the need to identify the molecular target It is equivalent to immunogenicity

Question 2 of 10 An anti-drug antibody reduces exposure to a monoclonal antibody. Why might the clinical consequence differ between products?

The effect of reduced exposure depends on how concentration relates to each product's biological mechanism Reduced exposure always increases efficacy for all monoclonal antibodies Anti-drug antibodies affect only tolerability and never pharmacological activity All monoclonal antibodies require the same exposure to produce their effects

Question 3 of 10 A safety signal appears shortly after a manufacturing change. Which conclusion is scientifically appropriate at the initial assessment stage?

The manufacturing change establishes causality The temporal association warrants integrated evaluation of clinical, quality, batch and alternative-explanation evidence The event should be attributed to mechanism without reviewing product quality Manufacturing changes cannot affect biologically relevant properties

Question 4 of 10 For a product known to cause prolonged depletion of an immune-cell population, which additional case information would be particularly informative?

Blood counts, infection history and evidence of recovery Only the antibody's country of manufacture Only the patient's antibody isotype Whether the product belongs to the same therapeutic area as another antibody

Question 5 of 10 What is the key additional safety consideration for a receptor agonist compared with a receptor-blocking antibody?

The possibility of excessive or prolonged activation of the receptor The certainty that the receptor is expressed only in diseased tissue The absence of any dose or exposure relationship The inability of the antibody to affect normal physiology

Question 6 of 10 An antibody binds an antigen on both malignant cells and a normal immune-cell population and recruits immune effectors. Which factor is most important when evaluating potential safety consequences?

Whether the normal cells express the target and may therefore also be depleted Whether the antibody is fully human, regardless of its target distribution Whether the product is administered by injection rather than infusion Whether all Fc-containing antibodies cause the same degree of depletion

Question 7 of 10 Why must an antibody-drug conjugate be assessed as an integrated medicinal product rather than as an unconjugated antibody alone?

The payload and linker can materially determine exposure, toxicity and clinical events The antibody component has no role in target recognition Antibody-drug conjugates cannot undergo internalisation The target antigen is irrelevant once a payload is attached

Question 8 of 10 A receptor antibody removes receptors from the cell surface, causing effects that persist after the initial binding event. Which mechanistic feature is most relevant?

Receptor internalisation or downregulation Simple ligand neutralisation Antibody sequence humanisation Complement-independent formulation

Question 9 of 10 Which information should be preserved as case evidence rather than recorded as an established mechanism in an individual case report?

Reported symptoms, laboratory findings and clinical outcome The assessor's unconfirmed hypothesis about target-mediated causality Treatment dates and exposure information Relevant medical history and concomitant medicines

Question 10 of 10 What is the appropriate role of mechanism in a pharmacovigilance safety assessment?

To establish causality whenever an event is biologically plausible To generate and refine safety hypotheses that must be evaluated against empirical evidence To replace individual case assessment and epidemiological evidence To demonstrate that related products share every risk

QPPV.com

Knowledge Assessment: Monoclonal Antibodies—Classification by Mechanism of Action and Pharmacovigilance

Cookie Settings